Integra Lifesciences Holdings Stock Revenue
| IART Stock | USD 22.62 0.50 2.16% |
Integra LifeSciences Holdings fundamentals help investors to digest information that contributes to Integra LifeSciences' financial success or failures. It also enables traders to predict the movement of Integra Stock. The fundamental analysis module provides a way to measure Integra LifeSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integra LifeSciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.6 B | 1.7 B |
Integra | Revenue |
Integra LifeSciences Holdings Company Revenue Analysis
Integra LifeSciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Integra LifeSciences Revenue | 1.61 B |
Most of Integra LifeSciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integra LifeSciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Integra
Projected quarterly revenue analysis of Integra LifeSciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Integra LifeSciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Integra LifeSciences' stock price.
Integra Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Integra LifeSciences is extremely important. It helps to project a fair market value of Integra Stock properly, considering its historical fundamentals such as Revenue. Since Integra LifeSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Integra LifeSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Integra LifeSciences' interrelated accounts and indicators.
| 0.57 | 0.57 | -0.57 | 0.57 | 0.45 | ||
| 0.57 | 0.98 | -0.65 | 0.94 | 0.69 | ||
| 0.57 | 0.98 | -0.57 | 0.94 | 0.59 | ||
| -0.57 | -0.65 | -0.57 | -0.75 | -0.95 | ||
| 0.57 | 0.94 | 0.94 | -0.75 | 0.77 | ||
| 0.45 | 0.69 | 0.59 | -0.95 | 0.77 |
Click cells to compare fundamentals
Integra Revenue Historical Pattern
Today, most investors in Integra LifeSciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Integra LifeSciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Integra LifeSciences revenue as a starting point in their analysis.
Integra LifeSciences Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Integra Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Integra LifeSciences Holdings reported 1.61 B of revenue. This is 78.88% lower than that of the Health Care Equipment & Supplies sector and 36.86% lower than that of the Health Care industry. The revenue for all United States stocks is 82.93% higher than that of the company.
Integra Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.Integra LifeSciences is currently under evaluation in revenue category among its peers.
Integra LifeSciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Integra LifeSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Integra LifeSciences' managers, analysts, and investors.Environmental | Governance | Social |
Integra LifeSciences Institutional Holders
Institutional Holdings refers to the ownership stake in Integra LifeSciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Integra LifeSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Integra LifeSciences' value.| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Paradigm Capital Management, Inc. | 2024-12-31 | 1.4 M | Capital Research Global Investors | 2024-12-31 | 1.4 M | Lord, Abbett & Co Llc | 2024-12-31 | 1.3 M | Soleus Capital Management, L.p. | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1 M | Neuberger Berman Group Llc | 2024-12-31 | 919.5 K | Northern Trust Corp | 2024-12-31 | 892.4 K | Systematic Financial Management Lp | 2024-12-31 | 860.6 K | Blackrock Inc | 2024-12-31 | 11.1 M | Vanguard Group Inc | 2024-12-31 | 7.6 M |
Integra Fundamentals
| Return On Equity | -0.0044 | ||||
| Return On Asset | 0.0291 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 3.44 B | ||||
| Shares Outstanding | 77.22 M | ||||
| Shares Owned By Insiders | 14.22 % | ||||
| Shares Owned By Institutions | 91.27 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | 26.94 X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 1.11 X | ||||
| Revenue | 1.61 B | ||||
| Gross Profit | 959.12 M | ||||
| EBITDA | 193.29 M | ||||
| Net Income | (6.94 M) | ||||
| Cash And Equivalents | 451.52 M | ||||
| Cash Per Share | 5.41 X | ||||
| Total Debt | 215.38 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 20.03 X | ||||
| Cash Flow From Operations | 129.38 M | ||||
| Short Ratio | 6.04 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Price To Earnings To Growth | 1.12 X | ||||
| Target Price | 26.25 | ||||
| Number Of Employees | 4.4 K | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 1.79 B | ||||
| Total Asset | 4.04 B | ||||
| Retained Earnings | 939.91 M | ||||
| Working Capital | 159.56 M | ||||
| Current Asset | 438.5 M | ||||
| Current Liabilities | 139.13 M | ||||
| Net Asset | 4.04 B |
About Integra LifeSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.